drugset / Trial / NCT00038532
Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to study amprenavir/ritonavir, saquinavir/ritonavir or efavirenz in HIV-infected patients following failure with Kaletra (ABT-378/ritonavir) as their first protease inhibitor based HAART.
Timeline
- Start
- 2001-04
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amprenavir | Other / unclassified | — | — |
| Subject | Efavirenz | Other / unclassified | — | — |
| Subject | Ritonavir | Other / unclassified | — | — |
| Subject | Saquinavir | Small molecule | — | — |